Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Osemozotan Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Osemozotan hydrochloride, Osemozotan hcl, 137275-80-0, Mkc-242, F0wkfypql8, 137275-80-0 (hcl)
    Molecular Formula
    C19H22ClNO5
    Molecular Weight
    379.8  g/mol
    InChI Key
    GGNCUSDIUUCNKE-RSAXXLAASA-N
    FDA UNII
    F0WKFYPQL8
    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride
    2.1.2 InChI
    InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1
    2.1.3 InChI Key
    GGNCUSDIUUCNKE-RSAXXLAASA-N
    2.1.4 Canonical SMILES
    C1C(OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl
    2.1.5 Isomeric SMILES
    C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    F0WKFYPQL8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride

    2. Mkc 242

    3. Mkc-242

    4. Osemozotan

    2.3.2 Depositor-Supplied Synonyms

    1. Osemozotan Hydrochloride

    2. Osemozotan Hcl

    3. 137275-80-0

    4. Mkc-242

    5. F0wkfypql8

    6. 137275-80-0 (hcl)

    7. Osemozotan (hydrochloride)

    8. Mkc 242

    9. 1,4-benzodioxin-2-methanamine, N-[3-(1,3-benzodioxol-5-yloxy)propyl]-2,3-dihydro-, Hydrochloride (1:1), (2s)-

    10. Mci-242

    11. 1,4-benzodioxin-2-methanamine, N-(3-(1,3-benzodioxol-5-yloxy)propyl)-2,3-dihydro-, Hydrochloride (1:1), (2s)-

    12. 5-(3-((2s)-(1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol

    13. Unii-f0wkfypql8

    14. 1,4-benzodioxin-2-methanamine, 2,3-dihydro-n-(3-(1,3-benzodioxol-5-yloxy)propyl)-, Hydrochloride, (s)-

    15. Schembl678900

    16. Dtxsid00929762

    17. Db05339

    18. Hy-100426a

    19. Cs-0018819

    20. 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride

    21. 3-[(2h-1,3-benzodioxol-5-yl)oxy]-n-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]propan-1-amine--hydrogen Chloride (1/1)

    22. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride, S-

    2.4 Create Date
    2005-08-09
    3 Chemical and Physical Properties
    Molecular Weight 379.8 g/mol
    Molecular Formula C19H22ClNO5
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count7
    Exact Mass379.1186505 g/mol
    Monoisotopic Mass379.1186505 g/mol
    Topological Polar Surface Area58.2 Ų
    Heavy Atom Count26
    Formal Charge0
    Complexity409
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.